Phytocannabinoids and gingival inflammation: Preclinical
findings and a placebo-controlled double-blind randomized
clinical trial with cannabidiol

J 2024

Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol

JIRASEK, Petr, Alexandr JUSKU, Jana FRANKOVA, Marketa URBANKOVA, Daniel DIABELKO et. al.

Basic information

Original name

Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol

Authors

Edition

JOURNAL OF PERIODONTAL RESEARCH, HOBOKEN, WILEY, 2024, 0022-3484

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.500 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/jre.13234

UT WoS

001157410200001

Keywords in English

cannabidiol; inflammation; microbiota; oral hygiene; periodontium; phytocannabinoid

Abstract

V originále

Objective: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis. Background: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease. Materials and Methods: Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase-1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo-control double-blind randomized study was conducted (56 days) in three groups (n = 90) using dental gel without CBD (group A) and with 1% (w/w) CBD (group B) and corresponding toothpaste (group A - no CBD, group B - with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD. Results: Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide-induced cells exhibited increased production of pro-inflammatory IL-6 and IL-8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis, with an MIC of 1.5 mu g/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days. Conclusions: Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry.

Citovat

JIRASEK, Petr, Alexandr JUSKU, Jana FRANKOVA, Marketa URBANKOVA, Daniel DIABELKO, Filip RŮŽIČKA, Barbora PAPOUSKOVA, Karin CHYTILOVA, Jiri VRBA, Jakub HAVLASEK, Katerina LANGOVA, Jan STORCH, Iva VOBORNA, Vilim SIMANEK and Jan VACEK. Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol. JOURNAL OF PERIODONTAL RESEARCH. HOBOKEN: WILEY, 2024, vol. 59, No 3, p. 468-479. ISSN 0022-3484. Available from: https://dx.doi.org/10.1111/jre.13234.

@article{2398862,
   author = {Jirasek, Petr and Jusku, Alexandr and Frankova, Jana and Urbankova, Marketa and Diabelko, Daniel and Růžička, Filip and Papouskova, Barbora and Chytilova, Karin and Vrba, Jiri and Havlasek, Jakub and Langova, Katerina and Storch, Jan and Voborna, Iva and Simanek, Vilim and Vacek, Jan},
   article_location = {HOBOKEN},
   article_number = {3},
   doi = {http://dx.doi.org/10.1111/jre.13234},
   keywords = {cannabidiol; inflammation; microbiota; oral hygiene; periodontium; phytocannabinoid},
   language = {eng},
   issn = {0022-3484},
   journal = {JOURNAL OF PERIODONTAL RESEARCH},
   title = {Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/jre.13234},
   volume = {59},
   year = {2024}
}

TY  - JOUR
ID  - 2398862
AU  - Jirasek, Petr - Jusku, Alexandr - Frankova, Jana - Urbankova, Marketa - Diabelko, Daniel - Růžička, Filip - Papouskova, Barbora - Chytilova, Karin - Vrba, Jiri - Havlasek, Jakub - Langova, Katerina - Storch, Jan - Voborna, Iva - Simanek, Vilim - Vacek, Jan
PY  - 2024
TI  - Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol
JF  - JOURNAL OF PERIODONTAL RESEARCH
VL  - 59
IS  - 3
SP  - 468-479
EP  - 468-479
PB  - WILEY
SN  - 00223484
KW  - cannabidiol
KW  - inflammation
KW  - microbiota
KW  - oral hygiene
KW  - periodontium
KW  - phytocannabinoid
UR  - https://onlinelibrary.wiley.com/doi/10.1111/jre.13234
N2  - Objective: The aim of this study was to: (1) evaluate the anti-inflammatory effects of cannabidiol (CBD) on primary cultures of human gingival fibroblasts (HGFs) and (2) to clinically monitor the effect of CBD in subjects with periodontitis. Background: The use of phytocannabinoids is a new approach in the treatment of widely prevalent periodontal disease. Materials and Methods: Cannabinoid receptors were analyzed by western blot and interleukin production detected using enzyme immunoassay. Activation of the Nrf2 pathway was studied via monitoring the mRNA level of heme oxygenase-1. Antimicrobial effects were determined by standard microdilution and 16S rRNA screening. In the clinical part, a placebo-control double-blind randomized study was conducted (56 days) in three groups (n = 90) using dental gel without CBD (group A) and with 1% (w/w) CBD (group B) and corresponding toothpaste (group A - no CBD, group B - with CBD) for home use to maintain oral health. Group C used dental gel containing 1% chlorhexidine digluconate (active comparator) and toothpaste without CBD. Results: Human gingival fibroblasts were confirmed to express the cannabinoid receptor CB2. Lipopolysaccharide-induced cells exhibited increased production of pro-inflammatory IL-6 and IL-8, with deceasing levels upon exposure to CBD. CBD also exhibited antimicrobial activities against Porphyromonas gingivalis, with an MIC of 1.5 mu g/mL. Activation of the Nrf2 pathway was also demonstrated. In the clinical part, statistically significant improvement was found for the gingival, gingival bleeding, and modified gingival indices between placebo group A and CBD group B after 56 days. Conclusions: Cannabidiol reduced inflammation and the growth of selected periodontal pathogenic bacteria. The clinical trial demonstrated a statistically significant improvement after CBD application. No adverse effects of CBD were reported by patients or observed upon clinical examination during the study. The results are a promising basis for a more comprehensive investigation of the application of non-psychotropic cannabinoids in dentistry.
ER  -

JIRASEK, Petr, Alexandr JUSKU, Jana FRANKOVA, Marketa URBANKOVA, Daniel DIABELKO, Filip RŮŽIČKA, Barbora PAPOUSKOVA, Karin CHYTILOVA, Jiri VRBA, Jakub HAVLASEK, Katerina LANGOVA, Jan STORCH, Iva VOBORNA, Vilim SIMANEK and Jan VACEK. Phytocannabinoids and gingival inflammation: Preclinical findings and a placebo-controlled double-blind randomized clinical trial with cannabidiol. \textit{JOURNAL OF PERIODONTAL RESEARCH}. HOBOKEN: WILEY, 2024, vol.~59, No~3, p.~468-479. ISSN~0022-3484. Available from: https://dx.doi.org/10.1111/jre.13234.

Detailed Information on Publication Record